Perspective: COVID-19 vaccine trials should seek worthwhile efficacy

COVID-19 vaccine trials should seek worthwhile efficacy – The Lancet

Commentary: Covid vaccine rush could make pandemic worse, say scientists – The Guardian

Commentary on Twitter

"Although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress"

Philip Krause et al for the @WHO Solidarity Vaccines Trial Expert Group on why #COVID19 vaccine trials should seek worthwhile efficacy https://t.co/2VWas8YU7L pic.twitter.com/RjbeZkeAE0

— The Lancet (@TheLancet) August 28, 2020